

One Casper Street
Danbury, CT 06810
Phone: 203-790-3121 Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials to study its safety and efficacy in the treatment of diabetes. This dry powder therapy consists of our proprietary Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using our proprietary MedTone inhaler. We believe that the performance characteristics, unique kinetics, convenience and ease of use of the Technosphere® Insulin System may have the potential to change the way diabetes is treated.
In order to deliver results, meet commitments and strive to be the best, our employees apply MannKind values in all aspects of work.
• Teamwork • Accountability • Quality• Communication • Integrity• Enthusiasm• Trust and Respect • Execution
As we work to improve the lives of people worldwide, we invite you to learn more about MannKind Corporation.
Website: http://www.mannkindcorp.com
Contact(s)
Daniel J. Giannini, Director, Human Resources
-
[email protected]
General Information
MannKind Corporation is a world-class biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products to treat diseases such as diabetes and cancer across the globe. Under the leadership of our Chairman and CEO, Al Mann, who has devoted his life to filling unmet medical needs, we use our proprietary technologies and breakthrough discoveries, striving to cure diseases and improve disease management.